SS-B/La Antibodies, IgG, Serum
Use
Evaluating patients with clinical features or at-risk for connective tissue disease, especially Sjögren syndrome. Anti-SS-B/La antibodies are primarily found in patients with SjS and, when present, can suggest a diagnosis of primary or secondary connective tissue disease if compatible autoantibody profile and clinical symptoms are present. The positive predictive value for primary Sjögren syndrome is increased with the positivity for antibodies to Ro52, Ro60, and SS-B/La. Combination of anti-SSB-B/A and anti-Ro52 and/or anti-Ro60 antibodies may also be useful in the phenotypic stratification of patients with primary Sjögren syndrome.
Special Instructions
Not provided.
Limitations
Low levels and/or single positivity for anti-SS-B/La antibodies are likely to have limited clinical significance for the diagnosis and phenotypic stratification of patients with primary Sjögren syndrome. Unlike antibodies to SS-A/Ro that are present in SjS and other connective tissue diseases and primary biliary cholangitis, anti-SS-B/La antibodies have limited significant association without SS-A/Ro presence.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex)
Biomarkers
LOINC Codes
- 33613-1 - ENA SS-B IgG Ser-aCnc
- 33613-1 - ENA SS-B IgG Ser-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.35 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |